Following on from information provided to NICE by the company in July 2016, the appraisal of Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATAT [ID857] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 857
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Liverpool Reviews and Implementation Group, University of Liverpool
Stakeholders
- Companies sponsors
- Imaging Equipment (lutetium-177 DOTATATE)
- Others
- Department of Health
- NHS England
- Welsh Government
- Professional groups
- British Nuclear Medicine Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiographers
- UK and Ireland Neuroendocrine Tumour Society (UKI NETS)
- Comparator companies
- Hospira UK - CAU not returned, not participating
- Ipsen - CAU not returned, not participating
- Novartis Pharmaceuticals UK - CAU not returned, not participating
- Sun Pharmaceuticals UK - CAU not returned, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2016, the appraisal of Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATAT [ID857] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 25 August 2016 | Invitation to participate |
| 25 August 2016 | Suspended. This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the company that markets lutetium-177 DOTATATE has informed us that they are not able to provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect. |
| 04 February 2016 | Draft scope documents |
| 14 January 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual